EP Patent

EP3321263A3 — Compounds for preparing hepatitis c virus inhibitors

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2018-07-04 · 8y expired

What this patent protects

The present disclosure relates to the preparation of a compound for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pyrrolidinyl or biphenyl derivatives which are used in a process for preparing the HCV inhibiting compound.

USPTO Abstract

The present disclosure relates to the preparation of a compound for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pyrrolidinyl or biphenyl derivatives which are used in a process for preparing the HCV inhibiting compound.

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP3321263A3
Jurisdiction: EP
Classification: —
Expires: 2018-07-04
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Holdings Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.